Singapore markets closed

Spyre Therapeutics, Inc. (SYRE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
37.51+2.32 (+6.59%)
As of 02:30PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close35.19
Open38.64
Bid37.17 x 100
Ask37.83 x 100
Day's range35.12 - 38.64
52-week range2.65 - 47.97
Volume310,170
Avg. volume494,941
Market cap1.511B
Beta (5Y monthly)2.93
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

    Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of inflammatory bowel disease ("IBD"), today announced its first quarter 2024 financial results and provided program and corporate updates.

  • PR Newswire

    Spyre Therapeutics Announces Grants of Inducement Awards

    Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 126,000 shares of common stock of Spyre to 4 non-executive empl

  • PR Newswire

    Spyre Therapeutics Announces $180 Million Private Placement

    Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of investigational antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fee